[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infective-endocarditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infective-endocarditis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,47,76,111,141,170,193,218,239,267,290,310,331,359,381,409,444,466,486,510,528],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645298","etiologic-diagnosis-algorithm-in-infective-endocarditis-100645298",false,"NCT07682389","Etiologic Diagnosis Algorithm in Infective Endocarditis","Development and Validation of An Algorithm of Etiological Diagnosis of Infective Endocarditis in Adults: An Open-Label Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Informed consent,\n* Age ≥ 18,\n* IE (definite or possible per the 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis)\n\nExclusion Criteria:\n\n* Pregnancy\u002Fbreastfeeding\n* Unconfirmed or rejected IE diagnosis,\n* Very high risk of death within 14 days due to severe complications of the main or concomitant disease(s), according to the physician's opinion;\n* Prior use of antibiotic therapy (except documented treatment failure).","ALL","18 Years",{"count":19,"type":20},128,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to evaluate the impact of a diagnostic algorithm combining culture-based and molecular methods on the frequency of etiotropic antibiotic therapy prescription within 14 days of diagnosis of infective endocarditis",[26,27],"Infective Endocarditis","Microbiology",[29,30,31,32,33],"Infective endocarditis","PCR","Antibiotic therapy","Etiological diagnosis","Sequencing","RECRUITING","2026-06-28",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2026-01-20",{"date":42,"type":20},"2027-02-20",{"name":44,"class":45},"I.M. Sechenov First Moscow State Medical University","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100619492","phase-3-rifampin-free-regimen-versus-rifampin-containing-regimen-in-the-treatment-of-staphylococcal-prosthetic-valve-endocarditis-100619492","NCT07345325","Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis","Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis: a Multicenter Randomized Controlled Non-inferiority Study","RIFREE","Inclusion Criteria:\n\n* Definite infective endocarditis according to the 2023 Duke ISCVID criteria or confirmed by the endocarditis team if the endocarditis was classified as possible\n* Prosthetic valve endocarditis\n* At least one positive blood culture due to Staphylococcus sp (S. aureus or CoNS)\n* After the first positive blood culture, at least one negative blood culture (after a minimum of 72 hours of incubation)\n* Infective endocarditis due to Staphylococcus sp (S. aureus or coagulase negative staphylococci) susceptible to rifampin\n* Antistaphylococcal treatment for endocarditis introduced less than 14 days ago. We do not consider all antibiotic received before the first positive blood culture\n* Age ≥ 18-year-old\n* Informed, written consent obtained from patient or from patient's near in kin\n* Patient insured under a health insurance scheme\n* Patient with adequate contraceptive measure\n\nExclusion Criteria:\n\n* Presence of cardiovascular implanted electronic device with suspected device-related IE without removal of the device\n* Expected duration of follow-up \\\u003C6 months at the time of randomization\n* Patient moribund (expected to die in next 48 hours with or without treatment)\n* Patients already receiving more than 72 hours of rifampin for the endocarditis treatment prior to randomization\n* Positive blood cultures less than 72 hours before randomization\n* Medical history of infective endocarditis in the last 3 months\n* True allergy to rifampin or a severe intolerance to rifampin\n* Contraindication to rifampin\n* Patients requiring treatment contraindicated or not recommended with rifampin or incompatible with the inducer effect of rifampicin according to the marketing authorisation.\n* ALAT increase greater than 3 times the upper laboratory range\n* Extreme weight (\\\u003C 45 kg or \\> 150 kg)\n* Patients with confirmed prosthetic vascular graft infection or orthopedic-device-related infection\n* Patients treated with rifampin for infections other than endocarditis, such as tuberculosis\n* Pregnancy or breastfeeding woman\n* Inclusion in another drug clinical trial\n* Patients who have already been included in the study for a previous episode of endocarditis\n* Patients under court protection, guardianship or trusteeship\n* Patients who do not speak or understand French language\n* Patient unable to collect information in a daily journal\n* Patient unable to understand a follow-up by phone contact",{"count":56,"type":20},422,[58],"PHASE3","The primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months after randomization.",[26],[62,63,64,65],"infective endocarditis","prosthetic valve","Rifampin","Staphylococcus aureus","2026-06-16",{"date":68,"type":38},"2026-06-17",{"date":70,"type":38},"2026-06-11",{"date":72,"type":20},"2031-06-11",{"name":74,"class":45},"Nantes University Hospital",31,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":46},"100635277","phase-2-oritavancin-for-treatment-of-serious-cardiac-infections-100635277","NCT07550595","Oritavancin for Treatment of Serious Cardiac Infections","A Multicentre Phase II Prospective Pilot Study of Pharmacokinetic- and TDM-guided Oritavancin Dosing Strategies for the Management of Gram-positive Cardiac Infections (the OSCAR Study)","OSCAR","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalised for management of a cardiac infection (infective endocarditis or cardiovascular implantable electronic device infections)\n3. Gram-positive organism identified in blood or tissue culture, that in the opinion of the investigator is the cause of cardiac infection and would be treatable with a finite antibiotic duration (e.g., 4-6 weeks)\n4. Afebrile for at least 24 hours at screening\n5. Clearance of blood cultures for at least 24 hours at screening\n6. Receiving effective antibiotic therapy for at least 24 hours and no more than 14 days at screening\n7. Willingness of both treating provider and participant to proceed with oritavancin therapy\n8. Able to provide written informed consent\n9. Willingness and ability to participate in study procedures, including follow-up visits and drug monitoring\n\nExclusion Criteria:\n\n1. History of severe allergic reaction or hypersensitivity to oritavancin or any of its components\n2. Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or currently receiving dialysis\n3. Severe hepatic impairment (Child-Pugh class C)\n4. Current infection involving the central nervous system, including septic emboli, ischemic or haemorrhagic stroke, epidural abscess, or meningitis (excluding prior\u002Funrelated central nervous system events).\n5. Presence of prosthetic heart valve\n6. Culture negative endocarditis\n7. Presence of any other active infection requiring concurrent antibiotic treatment that could interfere with study outcomes\n8. Infection with Gram positive organism not susceptible to oritavancin or vancomycin (vancomycin MIC \\> 2 μg\u002FmL).\n9. Use of contraindicated medications (see Section 8)\n10. Participation in another interventional clinical trial that may confound study outcomes\n11. Pregnant or breastfeeding people, or those planning to become pregnant during the study period (people of childbearing potential must have a negative pregnancy test during hospitalization and use effective contraception for trial duration and for 3 months after last infusion of study medication).\n12. Immunosuppression (defined as active chemotherapy expected to cause absolute neutrophil count \\\u003C100 cells\u002Fmm3 lasting \\>7 days during the study period, bone marrow transplantation in the preceding 90 days, solid organ transplantation within prior 3 months or receipt of augmented immunosuppression for rejection within 3 months, chronic granulomatous disease, HIV with a CD4 count \\\u003C50 cells\u002Fmm3 based on last known measure).\n13. Any condition (e.g. severe cognitive impairment, psychiatric illness, active withdrawal) that, in the opinion of the investigator, would limit the participant's ability to comply with study procedures or give informed consent\n14. Medically unstable in opinion of treating clinician that would preclude participation\n15. Cases in which the investigator deem curative or finite antibiotic treatment unlikely (e.g., long term indefinite suppressive antibiotics are likely such as retained hardware).",{"count":85,"type":20},20,[87],"PHASE2","Cardiac infections, including infective endocarditis and cardiovascular implantable electronic device infections, are associated with substantial morbidity and mortality and are commonly caused by gram-positive bacteria. Standard management typically requires prolonged courses of intravenous antibiotics and extended hospitalisation, which are costly, burdensome, and associated with complications related to long-term vascular access. People who inject drugs are disproportionately affected and often experience stigma, barriers to care, and poorer outcomes. Long-acting lipoglycopeptides such as oritavancin maintain therapeutic serum concentrations for prolonged periods and may offer an alternative to conventional intravenous antibiotic regimens. Oritavancin is not TGA-registered in Australia and is accessed as an unregistered medicine (for example, via SAS or clinical trials). It is approved in other jurisdictions, including the United States and European Union, for acute bacterial skin and skin structure infections. Prospective data in cardiac infections remain limited, and optimal dosing strategies, including the role of therapeutic drug monitoring, are uncertain. This multicentre, open-label pilot study will assess the feasibility, pharmacokinetics, safety, acceptability, and preliminary efficacy of oritavancin for gram-positive cardiac infections using both standard fixed dosing and TDM-guided dosing strategies. Findings will inform PK\u002FPD modelling, the potential role of TDM, and the design of future larger-scale trials and models of care, including alternatives to prolonged inpatient intravenous therapy.",[26,90,91],"Cardiac Device Infection","Gram-positive Bacterial Infections",[93,94,95,29,96,97,98,99],"Oritavancin","Long-acting antibiotic","Lipoglycopeptide","Cardiac device infection","Gram-positive infection","Therapeutic drug monitoring","Pharmacokinetics","NOT_YET_RECRUITING","2026-04-23",{"date":103,"type":38},"2026-04-29",{"date":105,"type":20},"2026-07-01",{"date":107,"type":20},"2028-09-30",{"name":109,"class":110},"Kirby Institute","OTHER_GOV",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":121,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100548211","infectious-disease-registry-biobank-100548211","NCT06418048","INfectious DIsease REgistry BIObank","Prospective Registry and Biobank of Patients With Infectious Diseases","INDI-REBIO","Inclusion Criteria:\n\n* Patients with clinically suspected or microbiologically documented infectious diseases (bacterial, viral, fungal or parasitic);\n* At least 18 years of age or older;\n* Able to provide informed consent;\n* Participants who are unable to understand the study protocol or are unable to give informed consent, but have a legal representative\n\nExclusion Criteria:\n\n\\- Participants who are unable to understand the study protocol or are unable to give informed consent, and have no legal representative.",{"count":120,"type":20},10000,"20 Years","OBSERVATIONAL","Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.",[125,126,127,128,26,129,130],"Bloodstream Infections","Central Nervous System Infections","Bone and Joint Infections","Endovascular Infections","CIED-related Infections","Vertebral Osteomyelitis","2026-04-15",{"date":133,"type":38},"2026-04-20",{"date":135,"type":38},"2024-02-01",{"date":137,"type":20},"2044-07-31",{"name":139,"class":45},"IRCCS San Raffaele",1,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":140},"100570192","healthrelated-quality-of-life-and-experiences-of-a-heart-rehabilitation-programme-after-care-for-infective-endocarditis-100570192","NCT06704048","Healthrelated Quality of Life and Experiences of a Heart Rehabilitation Programme After Care for Infective Endocarditis.","Healthrelated Quality of Life and Experiences of a Heart Rehabilitation Programme After Care for Infective Endocarditis. A Quantitave and Qualitative Study With Mixed Methods.","Inclusion Criteria:\n\n* Diagnosis of infective endocarditis (IE) based on Dukes ISCVID criteria and discharged after treatment for IE from the Department of Infectious Diseases, Hospital of Halmstad, Region Halland, Sweden.\n\nExclusion Criteria:\n\n* Not able to do a bicycle ergometer test or training.","90 Years",{"count":150,"type":20},50,[23],"How does health develop after Infective endocarditis (IE)? Can the health of patients with IE be improved by participation in the physical exercise training within cardiac rehabilitation program?\n\nParticipants will:\n\n* Answer digitally surveys on the perceived health for 4 times during 1 year\n* Participate in interviews on patient's experiences of health and rehabilitation 1 time before and 2 times after the training program during I year.\n* Be physically evaluated by a physiotherapist before and after the progam of physical exercise training within cardiac rehabilitation.\n* Do individual exercises in a group led by a physiotherapist 2 times weekly during 12 weeks.",[26,154,155,156],"Bacterial Infections","Cardiac Rehabilitation","Patient Participation",[26,154,156,158,159,160],"Interview","Qualitative Research","Cardiac rehabilitation","2026-04-01",{"date":163,"type":38},"2026-04-07",{"date":165,"type":38},"2024-08-22",{"date":167,"type":20},"2035-08",{"name":169,"class":45},"Region Halland",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},"100536811","cbct-vs-opt-on-the-oral-health-status-at-12-months-of-patients-hospitalized-for-infective-endocarditis-100536811","NCT06269679","CBCT vs OPT on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis.","3D Imaging (Cone Beam Computed Tomography) Versus Orthopantomogram on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis: a Multicenter Randomized Superiority Controlled Trial.","3D STARS","Inclusion Criteria:\n\n1. Patients hospitalized or recently hospitalized for definite IE according to the 2015 ESC classification, naive patients for dental examination and imaging, whatever the IE responsible microorganism;\n2. Patients with a stable clinical state, meaning stabilized IE patients out of the critical phase, compatible with the performance of an OPT and a CBCT;\n3. Patients whose life expectancy is expected to be longer than 6 months;\n4. Patients who agree to visit the dental department of the hospital to carry out OIF eradication or at his\u002Fher personal dentist;\n5. Patients over 18 years old;\n6. Patients affiliated to a Social Security or a health insurance scheme;\n7. Patients who have given informed consent to participate to the study.\n\nExclusion Criteria:\n\n1. OPT or CBCT already performed before the inclusion of the patients in the study and available for the investigator during the patient's hospitalization.\n2. Medical contraindications to perform OPT or CBCT imaging;\n3. Absence of microbiologic identification of the IE responsible microorganism;\n4. Pregnant or breastfeeding women;\n5. Patients unable to give informed consent to participate to the study (under trusteeship, guardianship and legal protection).","100 Years",{"count":180,"type":20},170,[23],"1\\. Infective Endocarditis (IE) is a rare and serious disease with high morbidity and mortality; 2. Streptoccoci of oral origin are the second more frequent microorganisms responsible for IE; 3. Oral Infectious Foci (OIF) are underdetected using the current recommended clinical examination\u002FOrthopantomogram (OPT) approach; 4. Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF than OPT; 5. To date, no study has been performed to assess the potential benefit of a clinical examination\u002FCBCT approach on the oral health status in IE patients.\n\nThus, conducting a randomized controlled trial is highly desirable to assess the potential impact of a clinical examination\u002FCBCT approach on the oral health status of patients hospitalized for IE and potentially to reduce IE new episodes.",[26],"2026-03-31",{"date":186,"type":38},"2026-04-06",{"date":188,"type":38},"2024-12-18",{"date":190,"type":20},"2028-07-18",{"name":74,"class":45},10,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":140},"100473552","phase-2-contribution-of-petct-with-gallium-68-citrate-68ga-petct-for-the-diagnosis-of-prosthetic-valve-infective-endocarditis-100473552","NCT05446376","Contribution of PET\u002FCT With Gallium 68 Citrate (68Ga-PET\u002FCT) for the Diagnosis of Prosthetic Valve Infective Endocarditis","CiGal-EI-TEP","Inclusion Criteria:\n\n* adult patient (over 18 years old);\n* patient with a prosthetic heart valve;\n* patient suspected of infective endocarditis (on clinical and\u002For microbiological and\u002For imaging data);\n* patient whose history is discussed in the multidisciplinary meeting dedicated to endocarditis;\n* patient beneficiary of a social security scheme;\n* free, informed and written consent signed by the participant and the investigator.\n\nExclusion Criteria:\n\n* pregnant or breastfeeding women;\n* women of childbearing potential not using effective contraception;\n* patients referred to in articles L.1121-5 to L.1121-8 (persons deprived of liberty by judicial or administrative decision, minors, adults subject to a legal protection measure or unable to express their consent);\n* subject in a period of relative exclusion due to another protocol;\n* known contraindication to PET\u002FCT with injection of radiotracers (hypersensitivity to radiopharmaceuticals and\u002For excipients).",{"count":201,"type":20},40,[87],"CiGal-EI-TEP is an exploratory study that aim to assess the diagnostic performance of 68Ga Positron emission tomography (PET) \u002F Computed Tomography (CT) for the diagnosis of prosthetic valve infective endocarditis in comparison with the final diagnosis established according to the ESC 2023 criteria, after 3 months of follow-up, by a panel of experts.",[26],[63,206,207,208,62],"PET\u002FCT","Gallium 68","diagnosis","2026-01-30",{"date":211,"type":38},"2026-02-03",{"date":213,"type":38},"2024-11-22",{"date":215,"type":20},"2026-11",{"name":217,"class":45},"University Hospital, Bordeaux",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100412190","betalactam-pharmacokinetics-in-endocarditis-patients-100412190","NCT04647331","Betalactam Pharmacokinetics in Endocarditis Patients","Inclusion Criteria:\n\n* Verified or suspected left or right sided endocarditis in native or prosthetic valve\n* Intravenous antibiotic therapy with either ampicillin, penicillin G, cefotaxime or cloxacillin\n* Signed informed consent to participate in study\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Ongoing dialysis",{"count":225,"type":20},150,"Infectious endocarditis (IE) is associated with mortality rates of 10-12%. Adequate antibiotic therapy is crucial for survival and is administered in high doses due to the severity of the disease. In most cases, beta-lactam antibiotics (e.g. ampicillin, penicillin G, cefotaxime or cloxacillin) are employed. A number of patient characteristics, such as age, body weight, and renal function) influence the pharmacokinetics of these drugs. Yet, the interindividual variability is poorly understood meaning that a large proportion of patients are at risk of subtherapeutic or excessive drug concentrations that might result in treatment failure or side effects, respectively.\n\nIn the present study, data will be collected on antibiotic concentrations in patients treated with beta-lactams for infectious endocarditis as well as patient characteristics and treatment outcomes. A mathematical model will be developed to determine which patient factors determine drug pharmacokinetics. Based on this model, predictions will be made by mathematical simulations on which dosing regimens are optimal for individual patients to ensure therapeutic and non-toxic drug concentrations. In total, 150 patients will be included at four University Hospitals in Sweden; Uppsala University Hospital, Sahlgrenska University Hospital in Gothenburg, Skåne University Hospital in Lund and Karolinska University Hospital in Stockholm. Following informed consent to participate blood samples will be collected at 6 time-points during a dose interval and then at 3 time-points weekly during the full treatment episode (maximum 6 weeks).",[26],[26],"2025-12-08",{"date":231,"type":38},"2025-12-17",{"date":233,"type":38},"2021-06-01",{"date":235,"type":20},"2025-12-31",{"name":237,"class":45},"Uppsala University",4,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":140},"100551230","echocardiography-versus-no-echocardiography-in-s-aureus-bacteraemia-and-virsta-score--3-100551230","NCT06457386","Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score \u003C 3","Echocardiography Versus no Echocardiography in Individuals With Staphylococcus Aureus Bacteremia and a VIRSTA Score \u003C3: a Non-inferiority Randomized Controlled Trial","VIRSTA-VAL","Inclusion criteria\n\n* Volunteers over 18 years of age;\n* Hospitalized with at least one blood culture positive for Staphylococcus aureus;\n* At the time of inclusion, negative control blood culture performed 48 hours after the first Staphylococcus aureus blood culture collection;\n* VIRSTA score \\\u003C 3; Exclusion criteria\n* Patient with catheter colonization without SAB, defined as positive blood cultures only through vascular access device specimen;\n* Patient referred to the hospital for the management of IE;\n* Contra indication to transthoracic echocardiography (TTE);\n* Echocardiography already performed before inclusion (TTE or TEE) for the current SAB;\n* Pregnancy;\n* Patient under guardianship or trusteeship.\n* Absence of written informed consent from the patient\n* No affiliation to social security (beneficiary or assignee)\n* Subject already involved in another interventional clinical research for which echocardiography must be done\"",{"count":248,"type":20},700,[23],"Staphylococcus aureus is the most frequent cause of both healthcare-associated and community-acquired bloodstream infections worldwide. Infective endocarditis (IE) has been detected in 5-17% of cases and is a determinant of poor prognosis. The investigators developed a score (the VIRSTA score) based on patients' characteristics to rule out IE with high confidence (negative predictive value (NPV) above 99%) in patients with SAB. This score, with a cut-off of 3 has been externally validated by two international studies which have also established its high NPV. The 2023 European society of cardiology (ESC) guidelines state that echocardiography should be considered in all patients with Staphylococcus aureus bacteremia (SAB) using risk scores (including VIRSTA score) to guide the use or not of echocardiography. While recommended, the investigators think that VIRSTA score must be evaluated in terms of patients' outcome.",[252,253,26],"Staphylococcus Aureus","Bacteremia",[255,256,257,29],"VIRSTA score \u003C 3","Staphylococcus aureus bacteraemia","Echocardiography","2025-11-19",{"date":260,"type":38},"2025-11-24",{"date":262,"type":38},"2025-05-14",{"date":264,"type":20},"2028-12",{"name":266,"class":45},"Assistance Publique - Hôpitaux de Paris",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":276,"studyType":122,"phases":4,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":140},"100438718","prospective-cohort-study-of-patients-with-infective-endocarditis-at-piti-salptrire-hospital-100438718","NCT04992923","Prospective Cohort Study of Patients With Infective Endocarditis at Pitié-Salpêtrière Hospital","Prospective Cohort Study of Patients With Infective Endocarditis Admitted at Cardiology Institute of Pitié-Salpêtrière Hospital","EIPSL","Inclusion Criteria:\n\n* Patients with confirmed IE according to European Society of Cardiology criteria\n\nExclusion Criteria:\n\n* Opposition of the patient to participate",{"count":248,"type":20},"12 Months","Infective endocarditis (IE) is a severe condition associated with high mortality. Due to the relative low prevalence of IE, prospective data are lacking and current guidelines are mostly based on expert consensus with low level of evidence. IE is also associated with severe complications especially strokes that occur in about one third of the patients.\n\nIn order to improve the management and the prognosis of IE, clinical data from larges prospective cohort studies are needed.",[26],[280,281],"Infective endocarditis, prospective,","prognosis, biomarker, embolism","2025-11-18",{"date":284,"type":38},"2025-11-21",{"date":286,"type":38},"2020-09-15",{"date":288,"type":20},"2041-03",{"name":266,"class":45},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":140},"100306707","french-national-observatory-on-infective-endocarditis-100306707","NCT03272724","French National Observatory on Infective Endocarditis","ObservatoireEI","Inclusion Criteria:\n\n* Major Patient\n* Supported in one of the participating centers\n* The application of diagnostic classification criteria of Duke modified by Li is carried out after collection of all the data at the end of the patient's hospitalization. Only patients meeting criteria for definite or possible endocarditis will be included in the analyses.\n* Registered with the French social security system\n\nExclusion Criteria:\n\n• Refusal of the patient to participate.",{"count":298,"type":20},5000,"The objective of this observatory is to provide a national database of infective endocarditis, informed by all volunteer centers, using a standardized case report forms.\n\nSuch an observatory will describe the clinical profile, microbiological, therapeutic and evolving of infective endocarditis (IE); analyze the risk factors for the disease and its prognosis factors of evolution; describe management practices; evaluate and compare in the real drug treatment strategies (including antibiotics) and surgical.",[26],"2025-09-18",{"date":303,"type":38},"2025-09-23",{"date":305,"type":38},"1991-01-01",{"date":307,"type":20},"2027-12-31",{"name":309,"class":45},"Central Hospital, Nancy, France",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":319,"studyType":122,"phases":4,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100573373","belgian-infective-endocarditis-registry-100573373","NCT06745440","Belgian Infective Endocarditis Registry","BIER","\\> 18 yo",{"count":318,"type":20},300,"5 Years","The objective of this prospective observational registry is to study patients di-agnosed with infective endocarditis (IE) and to gather comprehensive long-term outcome data, including mortality rates and IE-related complications (e.g., thromboembolic events, (hospitalization for) heart failure, valve surgery and IE recurrence) at one, three-, and five-years post-enrollment. Additionally, the registry will document epidemiological characteristics, clinical presentation at baseline, biochemical and microbiological profiles, relevant comorbidities and risk factors, diagnostic strategies, and therapeutic interventions, including an-timicrobial therapy and surgical procedures.",[26],"2025-08-27",{"date":324,"type":38},"2025-08-28",{"date":326,"type":20},"2025-09-01",{"date":328,"type":20},"2033-12-31",{"name":330,"class":45},"Universitair Ziekenhuis Brussel",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":339,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":21,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":358},"100494715","reducing-risk-for-infective-endocarditis-100494715","NCT05721781","Reducing Risk for Infective Endocarditis","Reducing Risk for Infective Endocarditis (IE): A Randomized Trial of a Professional Scaling and Oral Hygiene Instruction Intervention to Reduce Tooth Brushing-Associated Bacteremia","PIE-B","Inclusion Criteria:\n\n* Age 18 years or older.\n* Greater than 6 months since last dental hygiene prophylaxis (cleaning).\n* 10 or more accessible teeth (including implants, with a minimum of 8 natural teeth).\n* Willing and able to provide informed consent.\n* Willing to comply with all study procedures and be available for the duration of the study.\n* Willing to forgo routine professional dental cleanings while enrolled in the trial.\n\nExclusion Criteria:\n\n* At high risk for IE, as defined by the 2007\u002F2021 AHA Guidelines:\n* Prosthetic cardiac valve or prosthetic material used for cardiac valve repair.\n* Previous episode of IE.\n* Cardiac transplantation recipient with cardiac valvulopathy.\n* Specific congenital heart disease conditions.\n* Pregnant, by self-report, or planning to become pregnant during the study period.\n* Affected by a condition that, in the opinion of the investigator, may preclude them from study completion or put them at increased risk such as :\n* Hemodialysis dependent.\n* Have a long-term intravascular catheter (e.g., for chemotherapy or parenteral nutrition).\n* Active injection drug use (IDU).\n* Clotting disorder such as, hemophilia.\n* Have a solid organ transplant or hematopoietic stem cell transplant, or ongoing treatment for hematologic cancer.\n* Currently incarcerated.\n* Systemic antibiotic use within the past 2 weeks.\n* Undergoing orthodontic treatment with fixed appliances (brackets and wires) or plans to do so during the study period.\n* Taking or requiring antibiotic prophylaxis prior to dental procedures for other reasons, e.g., to prevent prosthetic joint infection .\n* Three or more teeth with moderate to severe gingival hyperplasia.\n* Has clinically detectable emergent or urgent dental needs that, in the trained and calibrated Oral Examiner's opinion, would require definitive dental care during the study period.",true,{"count":341,"type":20},320,[23],"This clinical trial is studying if bacteria found in a participant's bloodstream after brushing their teeth can be prevented with a dental cleaning and more education on how to best brush and care for their teeth. One group of participants will have a dental cleaning and oral health instructions and the other group of participants will not. Researchers will compare the blood test results from the two groups to see if the education made a difference in preventing bacteria and how long it stays in the bloodstream.",[253,26],[346,347,348],"Oral Hygiene","Oral Bacteria","Gingival inflammation","2025-08-21",{"date":351,"type":38},"2025-08-22",{"date":353,"type":38},"2023-08-31",{"date":355,"type":20},"2027-09",{"name":357,"class":45},"Wake Forest University Health Sciences",6,{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":365,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":140},"100549437","barts-endocarditis-research-registry-100549437","NCT06434012","Barts Endocarditis Research Registry","Inclusion Criteria:\n\n* • Patients aged 16 and over (Patients under 16 years of age are not admitted to Barts Heart Centre)\n\n  * Patients admitted to Barts Heart Centre with confirmed Endocarditis (see above)\n  * Patients attending outpatients with confirmed\u002Fsuspected Endocarditis\n  * Patients with possible IE who complete treatment for endocarditis\n  * Patients with cardiac device related Endocarditis\n  * Patients with the ability to provide informed consent\n\nExclusion Criteria:\n\n* • Patients with pacemaker pocket infection with no evidence of pacemaker lead or valve infection\n\n  * Patients who refuse consent to be included in the research database\n  * Patients with \"rejected\" endocarditis","16 Years",{"count":367,"type":20},1000,"The Barts Endocarditis Research Registry is being set up to give a unique opportunity to assess the characteristics of Infective Endocarditis (IE) in our population cohort, the current use of imaging techniques, as well as the implementation of the ESC guidelines and its consequence in terms of prognosis. All this will help improve the diagnosis and management of IE. The registry will also form the core of all our subsequent work, including interventional studies. The endocarditis research registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment. We have a series of studies planned that we believe will influence the management of endocarditis (we are working up proposals for genomic and therapeutic trials that will subsequently be presented for ethical and hospital approval). The registry will be generic to all our planned studies, and will allow us to capture data to assess treatment effectiveness",[26,370,371],"Endocarditis","Endocarditis, Bacterial","2025-07-10",{"date":374,"type":38},"2025-07-15",{"date":376,"type":38},"2019-04-24",{"date":378,"type":20},"2029-04-30",{"name":380,"class":45},"Queen Mary University of London",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":21,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":408},"100595195","evaluation-of-the-impact-of-a-patient-education-protocol-on-the-quality-of-18f-fdg-pet-imaging-indicated-for-investigation-of-cardiac-inflammation-100595195","NCT07029295","Evaluation of the Impact of a Patient Education Protocol on the Quality of 18F-FDG PET Imaging Indicated for Investigation of Cardiac Inflammation","CARTEP","Inclusion Criteria:\n\n* Presence of a prescription validated by the nuclear medicine department for an 18F-FDG PET scan for the detection of inflammation of cardiac inflammation or infection\n* Age greater than or equal to 18\n* Membership of a social security scheme or equivalent\n* Patients with an e-mail address\n* Patients who understand French\n* Collection of patient consent\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding\n* Patients (inpatients or outpatients) already on a diet (including ketogenic)\n* Patients who do not understand protocol\n* Patients deprived of liberty by judicial or administrative decision\n* Patients under legal protection (guardianship\u002Ftrusteeship)\n* Patients under court protection",{"count":389,"type":20},138,[23],"The aim of this study is to assess the impact of implementing a patient education and preparation protocol for FDG PET (18F-FDG PET) imaging on the quality of imaging results.\n\n18F-FDG (18Fluor-FluoroDesoxyGlucose) PET (Positron Emission Tomography) is indicated for the diagnosis of cardiac inflammation. To detect cardiac inflammation, the myocardium (heart muscle) must be prevented from absorbing glucose from the diet (FDG). To achieve this, patient preparation is essential. Poor preparation can compromise the interpretation of results, causing diagnostic delay.\n\nTo answer the research question, the investigators plan to include 138 people with suspected infective endocarditis or cardiac sarcoidosis, in two institutions of the Assistance Publique - Hôpitaux de Paris: Hôpital Européen Georges Pompidou and Hôpital Cochin-Port-Royal, located respectively at 20 rue Leblanc 75015 Paris and 27 rue du Faubourg Saint-Jacques 75014 Paris.",[26,393],"Cardiac Sarcoidosis",[395,396,62,397,398,399],"18F-FDG","PET","cardiac sarcoidosis","patient preparation","patient education protocol","2025-06-11",{"date":402,"type":38},"2025-06-19",{"date":404,"type":20},"2025-07-01",{"date":406,"type":20},"2027-08-31",{"name":266,"class":45},2,{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":21,"phases":419,"briefSummary":420,"conditions":421,"keywords":428,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":140},"100593985","oritavancin-for-cied-infections-with-mdr-gram-positive-cocci-100593985","NCT07013552","Oritavancin for CIED Infections With MDR Gram-positive Cocci","Oritavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections With Multidrug-resistant Gram-positive Cocci","ORI-4-CIEDi","Inclusion Criteria:\n\n1. Completed 18 years of age\n2. Presence of signs and symptoms of superficial ABSSSI or PI in the form of a) redness\u002Fwarmth\u002Fswelling\u002Fpain or b) separation of the edges of the surgical incision with signs of inflammation or the need for repeated surgical debridement of the wound or c) the presence of decubitus of the skin and subcutaneous tissue in area of the generator or skin abscess\u002Ferosion of the device pocket, with purulent discharge from the wound or discharge giving a positive microbial culture\n3. Probable\u002F definite diagnosis of right-sided LRIE according to modified Dukes criteria (optional criterion)\n4. Suspected\u002Fconfirmed infection with drug-resistant Gram-positive cocci, i.e., Staphylococcus spp. (Stahphylococcus aureus or coagulase-negative staphylococci), Streptococcus spp. or Enterococcus spp. sensitive to oritavancin\n5. Suspected\u002Fconfirmed infection with Gram-positive cocci, i.e., Staphylococcus spp., Streptococcus spp., Enterococcus spp., sensitive to vancomycin or oritavancin and beta-lactam antibiotics in patients with a history of type I anaphylaxis to penicillin.\n\nExclusion Criteria:\n\n1. Suspected\u002Fconfirmed infection with Gram-positive or Gram-negative bacilli or anaerobic bacteria\n2. Suspected\u002Fconfirmed community-acquired infection or infection with Gram-positive cocci sensitive to betalactam antibiotics, including penicillin, ampicillin, or methicillin, based on empirical data or cultures (does not apply to patients with a history of type I anaphylaxis to penicillin)\n3. Confirmed resistance of Gram-positive cocci, which are the etiological factor of the infection, to vancomycin and oritavancin.\n4. History of hypersensitivity to oritavancin or another lipoglycopeptide antibiotic (applies to the experimental group only)\n5. History of hypersensitivity to vancomycin or another glycopeptide antibiotics (applies to the control group only)\n6. No possibility of temporarily interrupting\u002Finitiating alternative therapy to intravenous infusion of unfractionated heparin\n7. Pregnancy or breastfeeding\n8. Lack of informed written consent of the patient to participate in the study",{"count":418,"type":20},100,[23],"The study aimed to conduct a randomized, non-inferiority controlled trial to compare the short- and medium-term efficacy and safety of two antibiotic dosage regimens in cardiac implantable electronic devices (CIED) infections with multidrug-resistant Gram-positive cocci: 1) single-dose therapy with a long-half-life antibiotic (oritavancin) vs. standard 7-14 days of therapy with a short-half-life antibiotic (vancomycin) for CIED surgical incision site or pocket infection; and 2) fractionated therapy with a long-half-life antibiotic (oritavancin) at seven-day intervals compared to standard therapy with a short-half-life antibiotic (vancomycin) fractionated in 2-3 daily doses in cases of lead-related infectious endocarditis.",[422,26,423,424,425,426,427],"Cardiac Implantable Electronic Device Infections","Multidrug-resistant Bacteria Screening","Gram Positive Bacterial Infection","Antibiotic Resistant Strain","Antibiotic Therapy","Healthcare Associated Infections",[429,430,431,432,433,434],"Cardiac implantable electronic device","Gram-positive cocci","Health-care associated infections","Lead-related infective endocarditis","Multidrug-resistant bacteria","Pocket infection","2025-06-02",{"date":437,"type":38},"2025-06-10",{"date":439,"type":20},"2025-06",{"date":441,"type":20},"2026-10",{"name":443,"class":45},"Medical University of Silesia",{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":358},"100423317","impact-of-fdg-petct-on-management-of-patients-with-native-valve-infective-endocarditis-100423317","NCT04792281","Impact of FDG-PET\u002FCT on Management of Patients with Native Valve Infective Endocarditis","PET-NAVIE","Inclusion Criteria:\n\n* 18 years of age or older, capable to provide informed consent;\n* Referred for a FDG-PET\u002FCT study\n* Classified as having Possible IE prior to FDG-PET\u002FCT imaging;\n* Patients must be able to tolerate the physical\u002Flogistical requirements of a PET\u002FCT scan.\n\nExclusion Criteria:\n\n* Subjects with prosthetic cardiac valve and\u002For CIED;\n* Pregnant or breastfeeding female;\n* Body mass index \\> 45 kg\u002Fm2.",{"count":452,"type":20},97,"The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.",[26,455],"Native Valve Endocarditis",[206,457,458],"FDG","Duke Criteria","2024-11-19",{"date":213,"type":38},{"date":462,"type":38},"2021-08-31",{"date":235,"type":20},{"name":465,"class":45},"Montreal Heart Institute",{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":140},"100560957","management-of-anemia-in-patients-with-endocarditis-infectious-candidates-for-cardiac-surgery-the-america-study-100560957","NCT06583902","Management of Anemia in Patients with EndocaRditis Infectious Candidates for Cardiac Surgery: the AMERICA Study","Management of Anaemia in Patients with Infectious Endocarditis Who Are Candidates for Cardiac Surgery: the AMERICA Trial","AMERICA","Inclusion Criteria: Patients with endocarditis who are candidates for elective surgery; Male and female patients aged \\> 18 years; Patients who have given written consent to participate in the study and to have their clinical data processed for the purposes of the study.\n\nExclusion Criteria: Age \\\u003C 18 years; Patients with hypersensitivity (bronchial asthma, urticaria, allergic phenomena) to preparations of intravenous iron, folic acid, vitamin B12, erythropoietin; Patients who have not given written consent to participate in the study and who have specifically refused the use of their clinical data for the purposes of the study; Patients participating in other investigational trials; Any other clinical condition that in the opinion of the investigator would make the patient unsuitable for the study",{"count":418,"type":20},"Infective endocarditis (EI) is an extremely serious disease requiring prolonged hospitalisation, complex management by multidisciplinary teams and high healthcare costs. Anemia is also emerging as a virtually constant condition associated with endocarditis, as evidenced by its inclusion in the variables used to calculate risk scores.Anemia associated with infective endocarditis (EI) has a remarkably complex and multifactorial pathogenesis.It is essential to treat anaemia in patients with EI as an integral part of their overall therapy, in what is now called patient blood management. Blood transfusion is not the only approach available to treat this condition. It is essential to correct any deficiencies, whether iron or vitamins. In addition, some patients may benefit from the administration of erythropoiesis-stimulating agents.",[26],"2024-09-02",{"date":479,"type":38},"2024-09-04",{"date":481,"type":20},"2024-10",{"date":483,"type":20},"2025-10-30",{"name":485,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":487,"slug":488,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":140},"100513430","prognosis-of-patients-with-infective-endocarditis-and-risk-stratification-value-of-biomarkers-endeavor-100513430","NCT05965362","Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）","Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR): a National Multi-center, Retrospective-prospective, Cohort Study Initiated by the Investigators","ENDEAVOR","Inclusion Criteria:\n\n* Patients with clinically confirmed infective endocarditis\n\nExclusion Criteria:\n\n* Patients refuse to sign informed consent form\n* Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples",{"count":495,"type":20},2000,"In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.",[26],[26,499,500],"Prognosis","Major Adverse Cardiac and Cerebrovascular event","2024-07-10",{"date":503,"type":38},"2024-07-12",{"date":505,"type":38},"2024-05-09",{"date":507,"type":20},"2028-12-31",{"name":509,"class":45},"First Affiliated Hospital Xi'an Jiaotong University",{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":526,"locationsCount":140},"100531024","the-incidence-clinical-characteristics-and-outcome-of-infective-endocarditis-among-intravenous-drug-abusers-versus-non-drug-abusers-100531024","NCT06194409","The Incidence, Clinical Characteristics and Outcome of Infective Endocarditis Among Intravenous Drug Abusers Versus Non-Drug Abusers.","Inclusion Criteria:\n\n* Adult Patients (\\>18 years) with definite or possible IE.\n\nExclusion Criteria:\n\n* Patients with rejected diagnosis of infective endocarditis after workup, according to modified Duke's criteria.",{"count":517,"type":20},46,"We aim to describe the incidence of IVDA among patients presented with IE, describe their clinical, psychiatric and microbiological characteristics in comparison to non - IVDA, as well as the rate and types of complications and outcome, and responsiveness to medical treatment or surgical intervention.",[26],"2024-06-23",{"date":522,"type":38},"2024-06-25",{"date":524,"type":38},"2024-05-05",{"date":439,"type":20},{"name":527,"class":45},"Assiut University",{"id":529,"slug":530,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":536,"targetDuration":319,"studyType":122,"phases":4,"briefSummary":537,"conditions":538,"keywords":541,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":408},"100482563","surgical-registry-of-endocarditis-europe-100482563","NCT05563662","SURgical Registry of ENDocarditis EuRope","SURgical Registry of Infective ENDocarditis in EuRope - SURRENDER","SURRENDER","Inclusion Criteria:\n\n* Patients with infective endocarditis (according to DUKE criteria) undergoing cardiac surgery\n* Age ≥18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Missing declaration of consent\n* Current participation in another interventional trial",{"count":120,"type":20},"This is a prospective, multicentric, european registry of patients with infective endocarditis undergoing cardiac surgery. Patient demographics, clinical data and laboratory values will be collected, as well as treatment outcomes at day 30, day 90 and 1-5 years after the intervention.",[26,539,540],"Cardiac Surgery","Outcomes",[26,542,543,544,499],"Registry","European","Surgery","2023-05-09",{"date":547,"type":38},"2023-05-10",{"date":549,"type":20},"2023-09",{"date":551,"type":20},"2033-04",{"name":553,"class":45},"University Hospital, Essen"]